Form 4 for DCOY Decoy Therapeutics Inc.
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001615219-23-000023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-15 | 2023-02-13 | DCOY | Arthur David J. | CEO, Dir | A - Grant | $0.00 | +14.3K | 48.0K | +42% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | A | A | 14,300 | $0.00 | 48,019 | D | — | — | (F1) Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement. |